HSBC Issues Positive Forecast for Bristol Myers Squibb (NYSE:BMY) Stock Price

Bristol Myers Squibb (NYSE:BMY) had its price objective increased by HSBC from $53.00 to $60.00 in a report published on Tuesday,Benzinga reports. The firm currently has a hold rating on the biopharmaceutical company’s stock.

Several other equities research analysts have also recently issued reports on BMY. Scotiabank reiterated a “sector perform” rating and set a $60.00 price objective (up from $53.00) on shares of Bristol Myers Squibb in a research report on Friday, January 9th. Barclays assumed coverage on shares of Bristol Myers Squibb in a research report on Thursday, February 19th. They set an “overweight” rating and a $75.00 target price for the company. Bank of America upgraded shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and lifted their price target for the company from $52.00 to $61.00 in a report on Monday, December 15th. Morgan Stanley reiterated an “underweight” rating and issued a $40.00 price target on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Finally, Royal Bank Of Canada initiated coverage on shares of Bristol Myers Squibb in a report on Tuesday, February 24th. They set a “sector perform” rating and a $60.00 price objective for the company. Nine investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Bristol Myers Squibb currently has an average rating of “Hold” and an average target price of $61.41.

Bristol Myers Squibb Stock Performance

NYSE BMY opened at $59.71 on Tuesday. The company has a quick ratio of 1.14, a current ratio of 1.26 and a debt-to-equity ratio of 2.32. Bristol Myers Squibb has a twelve month low of $42.52 and a twelve month high of $62.89. The business has a 50-day moving average price of $58.47 and a 200-day moving average price of $51.64. The firm has a market cap of $121.59 billion, a price-to-earnings ratio of 17.31, a price-to-earnings-growth ratio of 0.17 and a beta of 0.26.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The business had revenue of $12.50 billion for the quarter, compared to the consensus estimate of $12.24 billion. During the same period last year, the business posted $1.67 EPS. The firm’s revenue for the quarter was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities research analysts predict that Bristol Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Investors of record on Thursday, April 2nd will be paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.2%. The ex-dividend date of this dividend is Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 73.04%.

Hedge Funds Weigh In On Bristol Myers Squibb

Hedge funds have recently bought and sold shares of the business. Norges Bank bought a new stake in shares of Bristol Myers Squibb during the fourth quarter worth $1,947,272,000. AQR Capital Management LLC increased its stake in Bristol Myers Squibb by 172.6% in the 4th quarter. AQR Capital Management LLC now owns 25,796,905 shares of the biopharmaceutical company’s stock worth $1,391,485,000 after buying an additional 16,332,924 shares during the period. Charles Schwab Investment Management Inc. increased its stake in Bristol Myers Squibb by 16.8% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 70,802,680 shares of the biopharmaceutical company’s stock worth $3,277,456,000 after buying an additional 10,195,775 shares during the period. Arrowstreet Capital Limited Partnership lifted its holdings in Bristol Myers Squibb by 428.5% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 11,311,281 shares of the biopharmaceutical company’s stock valued at $523,599,000 after buying an additional 9,171,098 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its position in Bristol Myers Squibb by 47.0% in the 4th quarter. Bank of New York Mellon Corp now owns 24,495,875 shares of the biopharmaceutical company’s stock valued at $1,321,308,000 after buying an additional 7,837,485 shares during the period. Institutional investors own 76.41% of the company’s stock.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: HSBC raised its price target on BMY from $53 to $60 and kept a “hold” rating, signaling improved near-term analyst sentiment (though the new PT offers only ~0.5% upside from current levels). Benzinga
• Positive Sentiment: BMY reported that its investigational candidate BMS-986278 advanced through a key heart safety study (Phase 1 update), reducing development risk for that program and supporting pipeline value upside if subsequent data are favorable. TipRanks: BMS-986278 Update
• Neutral Sentiment: Zacks published a piece framing BMY as a strong value stock based on style scores and valuation metrics — a reminder that some investors are viewing BMY as a defensive, income-oriented pick rather than a high-growth biotech. Zacks: Value Stock
• Neutral Sentiment: Recent market commentary notes BMY has slightly outperformed recent market returns, reflecting stability from its commercial portfolio and dividend profile rather than fresh catalysts. Yahoo Finance: Market Performance
• Neutral Sentiment: Analyst comparisons (Pfizer vs. BMY) highlight competition in oncology and pipeline-driven M&A/portfolio moves; these comparisons keep investor focus on relative pipeline strength and strategic deals. Zacks: PFE vs BMY

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.